Selexipag Dosing Strategies for Pediatric Patients with Pulmonary Arterial Hypertension
Madeline Grossman, Stephen Walker, E. Zachary RamseyChildren’s Hospital of Philadelphia.United States Pediatric CardiologyPediatr Cardiol 2024; DOI: 10.1007/s00246-024-03513-w AbstractThis retrospective chart review of patients less than 18 years old with pulmonary arterial hypertension (PAH) receiving selexipag was conducted to describe selexipag dosing practices, impact on concomitant PAH therapies, and the safety and efficacy of selexipag. Twenty-seven patients
Selexipag Dosing Strategies for Pediatric Patients with Pulmonary Arterial Hypertension Read More »
